Stifel analyst adjusted price target for Lucid based on company results on August 30, 2025.
2 reports, 2 independent
Updated Aug 30
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Stifel analyst adjusted price target for Lucid based on company results on August 30, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Stifel analyst lowered Lucid's price target.1 source
Stifel analyst adjusted price target for Lucid on August 30, 2025.1 source
Keep exploring
The entities involved
Related events
- Stifel reiterated a Buy rating and target price for Spyre Therapeutics, while Deutsche Bank lowered targets following company results.
- Stifel lowered price target on Viking Holdings Ltd, citing European low-water risk. AQR Capital Management led by Cliff Asness tracks the company.
- Spyre Therapeutics, Inc. was listed on Nasdaq and received analyst ratings from firms including Deutsche Bank and Stifel.
- Morgan Stanley maintained Equal Weight rating, Stifel lifted target price from $90 to $107, and TD Cowen stuck to its Hold rating for a company (implied to be Elastic).
Coverage
Newest first; wire copies grouped- StockStoryWhy Lucid (LCID) Stock Is Trading Lower Today Shares of luxury electric car manufacturer Lucid (NASDAQ:LCID) fell 4.3% in the afternoon session after the company prepared to execute a reverse stock s
- Motley FoolWhy Lucid Stock Skidded to a More Than 4% Loss Today Your share price would probably wither too if you enacted a reverse stock split. Lucid's took effect after the market closed that day. 10 stocks w